Product Description
SKB315 is a third-generation antibody-drug conjugate (ADC) that incorporates an anti-Claudin 18.2 antibody conjugated to highly potent topoisomerase I inhibitor, via site-specific conjugation and highly stable linker. Preclinical studies showed promising anti-tumor activity in various solids tumors overexpressing Claudin 18.2. (Sourced from: https://www.kluspharma.com/pipeline)
Mechanisms of Action: CLDN18.2 Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sichuan Kelun Research Institute
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SKB315-I-01 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2024-05-31 |
27% |
| CTR20220285 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
None |